Bergallo Massimiliano, Gambarino Stefano, Pinon Michele, Barat Veronica, Montanari Paola, Daprà Valentina, Galliano Ilaria, Calvo Pier Luigi
Laboratory of Citoimmunodiagnostics, University Hospital City of Science and Health of Turin, Regina Margherita Children's Hospital, Piazza Polonia 94, 10126 Turin, Italy; Department of Public Health and Pediatric Sciences, University of Turin, Medical School, Piazza Polonia 94, 10126 Turin, Italy.
Laboratory of Citoimmunodiagnostics, University Hospital City of Science and Health of Turin, Regina Margherita Children's Hospital, Piazza Polonia 94, 10126 Turin, Italy.
J Clin Virol. 2017 Jun;91:36-41. doi: 10.1016/j.jcv.2017.04.002. Epub 2017 Apr 8.
Epstein-Barr virus (EBV) infects 90% of the world population, commonly causing self-limiting infectious mononucleosis or rarely inciting a range of malignancies. EBV microRNAs (miRNAs) were discovered by sequencing libraries of small RNAs generated from several EBV-positive cell lines. Little is known about their roles, but their high stability and easy quantification make these molecules potential biomarkers.
In this study a stem-loop MGB real-time RT-PCR has been used to detect and quantify miR-BART2-5p, miR-BART15 and miR-BART22 EBV miRNAs levels.
The profiles of EBV miRNAs levels were evaluated in 51 serum samples of 37 pediatric liver transplant patients subdivided in 3 study groups: EBV seronegative, EBV seropositive and PCR negative, EBV seropositive and PCR positive.
miR-BART22 serum levels in patients with positive EBV PCR were significantly higher than those in patients with negative EBV PCR (p=0.0005). On the contrary, miR-BART2-5p and miR-BART15 did not exhibit significant difference in positive and negative EBV PCR patients (p=0.5511 and p=0.3523, respectively).
This study described a method for quantitative detection of miR-BART 22, miR-BART2-5p and miR-BART15 EBV miRNAs in liver transplanted patients, and suggests the use of miR-BART22 as a potential biomarker for EBV reactivation.
爱泼斯坦-巴尔病毒（EBV）感染了全球90%的人口，通常引起自限性传染性单核细胞增多症，或极少引发一系列恶性肿瘤。EBV微小RNA（miRNA）是通过对多个EBV阳性细胞系产生的小RNA文库进行测序而发现的。人们对它们的作用知之甚少，但它们的高稳定性和易于定量使其成为潜在的生物标志物。
在本研究中，采用茎环MGB实时逆转录聚合酶链反应（RT-PCR）检测并定量miR-BART2-5p、miR-BART15和miR-BART22这几种EBV miRNA的水平。
在37例小儿肝移植患者的51份血清样本中评估EBV miRNA水平，这些患者被分为3个研究组：EBV血清学阴性、EBV血清学阳性且PCR阴性、EBV血清学阳性且PCR阳性。
EBV PCR阳性患者的血清miR-BART22水平显著高于EBV PCR阴性患者（p=0.0005）。相反，miR-BART2-5p和miR-BART15在EBV PCR阳性和阴性患者中未表现出显著差异（分别为p=0.5511和p=0.3523）。
本研究描述了一种定量检测肝移植患者中miR-BART 22、miR-BART2-5p和miR-BART15这几种EBV miRNA的方法，并提示miR-BART22可作为EBV再激活的潜在生物标志物。
